News

At the Envision Summit 2025 in San Juan, Puerto Rico, Lana Rifkin, MD, gave clinicians advice on how, and when it may be most appropriate to use the new G2211 code.

At the Envision Summit 2025 in San Juan, Puerto Rico, Arjan Hura, MD, talked about EVO ICL surgery, its benefits, and how every ophthalmologist has the ability and training to conduct the surgery even if they aren't aware.

At the Envision Summit 2025 in San Juan, Puerto Rico, Nita Valikodath, MD, MS, gave insight into a challenging case of a 14-year-old boy who had trauma-related retinal detachment in his right eye, where a further macula-on retinal detachment with retinal dialysis was found in the left.

At the Envision Summit 2025 in San Juan, Puerto Rico, Deepak Sambhara, MD, gave insight into the 96-week post hoc fluid outcomes analysis of patients who participated in the phase 3 clinical trial PULSAR.

At the Envision Summit 2025 in San Juan, Puerto Rico, Carol Karp, MD, discussed new research presented by her fellows at the meeting on AI for the diagnosis of ocular surface tumors as well as a new "tear biopsy" for the detection of cancer.

At the Envision Summit 2025 in San Juan, Puerto Rico, Brittany Simmons, MD, discussed periorbital injuries and how they can affect the soft tissue and bones around the eye and gives insight into how clinicians should best go about treating it.

At the Envision Summit 2025 in San Juan, Puerto Rico, Jessica Steen, OD, FAAO talked with glaucoma surgeons on the importance of comanaging patients throughout their lifetime.

Laxmi Devisetty, MD, and Eva Kim, MD, look ahead at upcoming sessions focusing on geographic atrophy and refractive and cataract surgery at the Envision Summit 2025.

The University of Bristol research team used animal models to compare patient responses to AAV therapy, studying male and female eye cells across different age groups (young, middle-aged and older patients)

The funding is allocated to support the clinical development of the company's non-incisional refractive correction procedure that leverages corneal cross-linking (CXL) to reshape the cornea.

A recent study of AEYE-DS AI technology used in conjunction with the Topcon NW500 resulted in exceptional clinical diagnostic efficacy.

The authors conducted a retrospective, cross-sectional study in which they described a technique for estimating the melanocytic choroidal tumor thickness using only Optomap UWF images.

The research team conducted a prospective study to assess any barriers to parental compliance with vision testing in preschoolers aged 3 to 6 years.

The approval follows a refiling after the FDA issued a Complete Response Letter due to language on the amended label.

Researchers used data from the UK Biobank to investigate the associations between a healthy lifestyle score and retinal neurovascular health.

Routine evaluation of meibomian glands, starting in childhood, is crucial for identifying and managing this progressive disease before it leads to long-term ocular surface issues.

Martin Friedlander, MD, PhD, discusses phase 3 macular telangiectasia findings, highlighting the potential for a decade-long alternative to intravitreal injections.

According to the company, the suffix “-mod” in urcosimod denotes its classification as a modulator of key inflammatory and neuropathic pathways.

The study’s main outcome measures were the changes in those 2 parameters following treatment with teprotumumab.

The rationale for the study was anecdotal reports of the effects of breast milk used by mothers to treat blocked tear ducts, rashes, and a chemical corneal burn in babies.

The trial will feature the company’s product candidate, AXV101, focused on combating childhood blindness due to retinitis pigmentosa (RP) caused by Bardet-Biedl Syndrome 1 (BBS1).

Yvonne Ou, MD, a professor of ophthalmology at the University of California San Francisco, spoke about lifestyle modifications for glaucoma at this year's Glaucoma 360 meeting.

Nathan Congdon, MD, highlights a recent study showing how virtual mentor-mentee relationships through Orbis' free telemedicine and e-learning platform can significantly enhance care.

The 2 phase II trials, Osprey and Apteryx successfully met all primary and secondary endpoints.

The 36-week trial was a randomized, double-masked, parallel-group, active-controlled, multicenter evaluating CLS-AX (axitinib injectable suspension) in participants with neovascular age-related macular degeneration.

M. Roy Wilson, presented the Shaffer-Hetherington-Hoskins Lecture at the Glaucoma 360 meeting held in San Francisco, California. This lecture was entitled, "Rethinking Race as a Risk Factor for Glaucoma: What Really Matters?"

Ooms' poster at the Association of University Professors of Ophthalmology annual meeting highlighted a study on gray area complications in strabismus surgery, showing that trainees are more likely than attendings to disclose these complications despite having similar baseline anxiety levels. Ooms is a PGY-4 ophthalmology resident at the Dean McGee Eye Institute.

Results were published from the phase 3 QUASAR trial and the extension study of the phase 3 PULSAR trial.